[go: up one dir, main page]

CL2019000266A1 - Composición de cannabis. - Google Patents

Composición de cannabis.

Info

Publication number
CL2019000266A1
CL2019000266A1 CL2019000266A CL2019000266A CL2019000266A1 CL 2019000266 A1 CL2019000266 A1 CL 2019000266A1 CL 2019000266 A CL2019000266 A CL 2019000266A CL 2019000266 A CL2019000266 A CL 2019000266A CL 2019000266 A1 CL2019000266 A1 CL 2019000266A1
Authority
CL
Chile
Prior art keywords
cancer
understanding
pharmaceutical composition
cannabis composition
symptom associated
Prior art date
Application number
CL2019000266A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CL2019000266A1 publication Critical patent/CL2019000266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UN MÉTODO PARA TRATAR EL CÁNCER O UN SÍNTOMA ASOCIADO CON EL CÁNCER. EN PARTICULAR, LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO PARA TRATAR EL CÁNCER O UN SÍNTOMA ASOCIADO CON EL CÁNCER, QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE LO NECESITE UNA CANTIDAD EFICAZ DE LA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN EXTRACTO DE CANNABIS QUE COMPRENDE Δ 9 -TETRAHIDROCANNABINOL (THC) EN UNA CANTIDAD DE DESDE 50 % A 99 % EN PESO DE LA COMPOSICIÓN FARMACÉUTICA.
CL2019000266A 2016-08-03 2019-01-31 Composición de cannabis. CL2019000266A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition

Publications (1)

Publication Number Publication Date
CL2019000266A1 true CL2019000266A1 (es) 2019-10-04

Family

ID=65524553

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000266A CL2019000266A1 (es) 2016-08-03 2019-01-31 Composición de cannabis.

Country Status (15)

Country Link
US (2) US11304925B1 (es)
EP (1) EP3493800A4 (es)
JP (2) JP2019526541A (es)
KR (3) KR20220132674A (es)
CN (1) CN109789123A (es)
AU (4) AU2017305103B2 (es)
BR (1) BR112019001794A2 (es)
CA (1) CA3031300A1 (es)
CL (1) CL2019000266A1 (es)
CO (1) CO2019001043A2 (es)
IL (1) IL264458B (es)
MX (1) MX386086B (es)
PE (2) PE20230607A1 (es)
SG (1) SG11201900501RA (es)
WO (1) WO2018023166A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190035791A (ko) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018232448A1 (en) 2017-06-19 2018-12-27 Zelda Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
CA3103178A1 (en) * 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
CN111263638A (zh) * 2017-09-15 2020-06-09 塞尔达治疗手术有限公司 用于治疗自闭症的组合物和方法
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
JP2021521277A (ja) * 2018-04-09 2021-08-26 エレヴェット・サイエンシズ 動物における疼痛の処置のためのアサ抽出物
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
US11946016B2 (en) 2018-06-14 2024-04-02 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020084423A1 (en) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Extraction-based contract execution
US20220040144A1 (en) * 2018-12-12 2022-02-10 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
NL2022615B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
AU2020258631B2 (en) * 2019-04-17 2023-11-02 Nordiccan A/S Fast disintegrating cannabinoid tablets
CA3154295A1 (en) * 2019-10-09 2021-04-15 Michael Foster DAVIS Aerosolisable material
CA3165437A1 (en) * 2019-12-19 2021-06-24 Steven Rothstein Extracts enriched with polyphenolic compounds and related methods
US20230348645A1 (en) * 2020-04-29 2023-11-02 Ligar Limited Partnership Imprinted polymers and methods for their use
BR112022025302A2 (pt) * 2020-06-12 2023-02-28 Zelira Therapeutics Operations Pty Ltd Composição e método para tratamento da dor crônica
KR20220126653A (ko) * 2021-03-08 2022-09-16 주식회사 엘지생활건강 칸나비게롤을 포함하는 조성물
WO2022215071A1 (en) * 2021-04-05 2022-10-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Compositions and methods for the treatment of cancer
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2025231524A1 (en) * 2024-05-08 2025-11-13 Heyday RX Pty Ltd Cannabinoid compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
EA200701246A1 (ru) 2004-12-09 2008-06-30 Инсис Терапьютикс, Инк. Стабильные при комнатной температуре составы дронабинола
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
CA2872528C (en) * 2012-05-03 2021-01-05 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising .delta.9-tetrahydrocannabinol and a method for preparing such an isolate
WO2014159688A1 (en) 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
PT3062606T (pt) * 2013-10-29 2019-07-17 Biotech Inst Llc Reprodução, produção, transformação e uso de canábis especial
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US10610512B2 (en) * 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
EP3217995A1 (en) * 2014-08-25 2017-09-20 Janing Holding ApS Device with compositions for delivery to the lungs, the oral mucosa and the brain
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
MX395015B (es) 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
US10502750B2 (en) * 2014-12-23 2019-12-10 Biotech Institute, Llc Reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
WO2016123475A1 (en) 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
PE20200676A1 (es) 2016-08-03 2020-06-11 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis
KR20190035791A (ko) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물

Also Published As

Publication number Publication date
CA3031300A1 (en) 2018-02-08
CN109789123A (zh) 2019-05-21
KR20220132674A (ko) 2022-09-30
BR112019001794A2 (pt) 2019-05-07
JP2019526541A (ja) 2019-09-19
CO2019001043A2 (es) 2020-06-19
AU2019203529B2 (en) 2021-04-29
KR20210129747A (ko) 2021-10-28
PE20230607A1 (es) 2023-04-13
EP3493800A4 (en) 2020-04-08
IL264458B (en) 2021-06-30
US20220202767A1 (en) 2022-06-30
AU2017305103A1 (en) 2018-07-05
AU2018100920B4 (en) 2019-02-07
MX2019001286A (es) 2019-06-13
AU2021205115B2 (en) 2023-06-15
AU2017305103B2 (en) 2019-02-21
MX386086B (es) 2025-03-18
KR20190034576A (ko) 2019-04-02
PE20200677A1 (es) 2020-06-11
SG11201900501RA (en) 2019-02-27
AU2021205115A1 (en) 2021-08-12
AU2018100920A4 (en) 2018-08-02
EP3493800A1 (en) 2019-06-12
IL264458A (en) 2019-02-28
KR102447510B1 (ko) 2022-09-27
JP7139559B2 (ja) 2022-09-21
AU2019203529A1 (en) 2019-06-06
US11304925B1 (en) 2022-04-19
WO2018023166A1 (en) 2018-02-08
NZ750272A (en) 2021-09-24
JP2021054836A (ja) 2021-04-08

Similar Documents

Publication Publication Date Title
CL2019000266A1 (es) Composición de cannabis.
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
CL2019000270A1 (es) Composición de cannabis.
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
CL2019000844A1 (es) Compuesto de piridina.
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
BR112017018092A2 (pt) composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX385372B (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe